M&A
confidence high
sentiment positive
materiality 0.60
Ocugen signs binding term sheet with Roots Pharmaceutical to license OCU400 in MENA; up to $255M milestones, 22% royalty
Ocugen, Inc.
- Upfront and near-term development milestones up to $4M; sales milestones up to $255M.
- Ocugen to receive 22% royalty on net sales of OCU400 in MENA region.
- Definitive license agreement expected within 90 days; Ocugen to manufacture supply.
- OCU400 is a modifier gene therapy for retinitis pigmentosa, a leading cause of inherited vision loss.